Literature DB >> 17916992

Antiphospholipid syndrome and cognition.

Bernardo Liberato1, Roger A Levy.   

Abstract

In addition to the well-defined neurologic events due to arterial and venous thrombotic vascular occlusions of antiphospholipid syndrome (APS), a broad spectrum of neuropsychiatric has been related to antiphospholipid (aPL). Experimental evidence of a pathogenic role of aPL in mice with impaired neurological function disclosed inflammatory reaction as a hallmark. The process that leads to neurological dysfunction seems to be both structurally destructive and functionally impairing. The most modern resources of neuroimmaging also suggest that, in addition to the micro-infarcts that occur in strategic areas, other metabolic impairments are related to progressive dementia and aPL presence. Although there is a lot of confusion among APS and lupus' cognitive involvement, there is a body of experimental and clinical evidence that aPL causes this kind of damage.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916992     DOI: 10.1007/s12016-007-0007-x

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  16 in total

1.  Anti-beta 2-glycoprotein I antibodies bind to central nervous system.

Authors:  B Caronti; V Pittoni; G Palladini; G Valesini
Journal:  J Neurol Sci       Date:  1998-04-01       Impact factor: 3.181

Review 2.  Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome).

Authors:  R Cimaz; P L Meroni; Y Shoenfeld
Journal:  Lupus       Date:  2006       Impact factor: 2.911

3.  Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data.

Authors:  Elizabeth Kozora; David B Arciniegas; Christopher M Filley; Misoo C Ellison; Sterling G West; Mark S Brown; Jack H Simon
Journal:  Cogn Behav Neurol       Date:  2005-09       Impact factor: 1.600

4.  Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model.

Authors:  L Ziporen; Y Shoenfeld; Y Levy; A D Korczyn
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

5.  Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes.

Authors:  J Chapman; M Cohen-Armon; Y Shoenfeld; A D Korczyn
Journal:  Lupus       Date:  1999       Impact factor: 2.911

6.  Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease.

Authors:  E Kozora; S G West; B L Kotzin; L Julian; S Porter; E Bigler
Journal:  Arthritis Rheum       Date:  1998-01

7.  Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus.

Authors:  R J Chinn; I D Wilkinson; M A Hall-Craggs; M N Paley; E Shortall; S Carter; B E Kendall; D A Isenberg; S P Newman; M J Harrison
Journal:  Arthritis Rheum       Date:  1997-01

8.  Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up.

Authors:  G Castellino; M Govoni; M Padovan; P Colamussi; M Borrelli; F Trotta
Journal:  Ann Rheum Dis       Date:  2005-01-07       Impact factor: 19.103

9.  Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells.

Authors:  B Caronti; C Calderaro; C Alessandri; F Conti; R Tinghino; C Pini; G Palladini; G Valesini
Journal:  J Autoimmun       Date:  1998-10       Impact factor: 7.094

10.  Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer.

Authors:  Y Shoenfeld; A Nahum; A D Korczyn; M Dano; R Rabinowitz; O Beilin; C G Pick; L Leider-Trejo; L Kalashnikova; M Blank; J Chapman
Journal:  Lupus       Date:  2003       Impact factor: 2.911

View more
  6 in total

1.  Vasculitis: current status and future directions.

Authors:  Pierre Youinou
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

2.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 3.  Cognitive impairment in antiphospholipid syndrome: evidence from animal models.

Authors:  Simone Appenzeller; Aline Tamires Lapa; Caio Rodrigues Guirau; Jozélio Freire de Carvalho; Yehuda Shoenfeld
Journal:  Clin Rheumatol       Date:  2012-01-05       Impact factor: 2.980

Review 4.  Cognitive dysfunction and antiphospholipid antibodies.

Authors:  Simone Appenzeller; Aline Tamires Lapa; Jozélio Freire de Carvalho; Fernando Augusto Peres; Yehuda Shoenfeld
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 5.  Immunoglobulin-mediated neuro-cognitive impairment: new data and a comprehensive review.

Authors:  Assaf Menachem; Joab Chapman; Yael Deri; Chaim G Pick; Aviva Katzav
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

6.  Antiphospholipid syndrome is an important modifiable risk factor of stroke in the young.

Authors:  Sujoy Khan
Journal:  Ann Indian Acad Neurol       Date:  2015 Jul-Sep       Impact factor: 1.383

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.